Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Number of holders
-
43
-
Total principal
-
323M
-
Principal change
-
-15.1M
-
Total reported value, excl. options
-
$320M
-
Value change
-
-$15.2M
-
Number of buys
-
13
-
Number of sells
-
-24
-
Price
-
$0.99
Significant Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q2 2021
42 filings reported holding 53220KAF5 - LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q2 2021.
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 has 43 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $323M of principal
.
Largest 10 bondholders include WOLVERINE ASSET MANAGEMENT LLC ($42.3M of principal), CANYON CAPITAL ADVISORS LLC ($40M of principal), LAZARD ASSET MANAGEMENT LLC ($36.5M of principal), AVIVA PLC ($31.5M of principal), Polygon Management Ltd. ($21.6M of principal), D. E. Shaw & Co., Inc. ($18.5M of principal), OAKTREE CAPITAL MANAGEMENT LP ($18.4M of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($15M of principal), STATE STREET CORP ($14.7M of principal), and Davidson Kempner Capital Management LP ($12.5M of principal).
This table shows the top 43 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.